Skip to content
lifestyle.phenomena.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Absci Corporation
Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors
June 24, 2026
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)
June 24, 2026
Absci to Participate in Upcoming Investor Conferences
May 20, 2026
Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results
May 8, 2026
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 4, 2026
Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026
April 23, 2026
Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference
April 8, 2026
Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results
March 24, 2026
Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic
March 24, 2026
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 6, 2026
1
2
Next Page
→